RFA-DK-22-013: Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 - Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $1.8 million to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 27, 2022.
From the official notice on Grants.gov, last changed August 24, 2022. Checked November 7, 2026.
- Award ceiling$1.8 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsOptional
- Funded byNIDDK
- Median yearly award$376,080
- Typical project length25 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-DK-22-013 were run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DK-22-013 in the NIH Guide.
Key dates
| Posted | August 24, 2022 |
|---|---|
| Deadline | October 27, 2022 |
| Archived by Grants.gov | December 2, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $376,080; it allows up to $1.8 million per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement is to invite applicationsfor for clinical centers for the continuation of the Drug-Induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA- DK-22-508) seeks to continue the Data Coordinating Center for DILIN. Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, dietary and herbal supplements have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 19 years, the DILIN throughout its publications has become the major source of information and progress in understanding the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide. The Network has made major advances in the understanding of the clinical presentation and outcomes of liver injury due to drugs as well as herbal and dietary supplements (HDS). These advances have led to exploratory inroads on the pathogenesis of DILI. DILIN remains the only structured, systematic and prospective effort in the United States and world-wide to characterize drug and HDS induced liver injury. The ultimate aims of DILIN are to elucidate the clinical and pathophysiologic features of DILI so as to allow inroads into its understanding, treatment and prevention, thus decreasing the burden of this disease.
Funded under RFA-DK-22-013 so far
NIH funded 5 projects under RFA-DK-22-013 in fiscal 2023 to 2026, at 5 institutions. The median yearly award was $376,080.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| University of North Carolina Clinical Center for DILIN | Univ of North Carolina Chapel Hill | 2026 | $375,531 |
| Michigan Hepatotoxicity Clinical Research Network Renewal | University of Michigan at Ann Arbor | 2026 | $377,430 |
| IU Clinical Center: Drug Induced Liver Injury Network | Indiana University Indianapolis | 2026 | $383,751 |
| Herbal and Dietary Supplement Induced Liver Injury in the U.S. | Thomas Jefferson University | 2026 | $375,582 |
| USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center | University of Southern California | 2026 | $348,884 |
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before
From fiscal 2021 to 2025, Diabetes, Digestive, and Kidney Diseases Extramural Research (93.847) awarded $9.6 billion across 7,877 grant awards, an average of $1.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 273 | $345 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | 187 | $272 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 209 | $238 million |
| The Washington University | Missouri | 187 | $227 million |
| The Regents of the University of California, San Francisco | California | 176 | $208 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DK-22-013 still open?
No. It closed on October 27, 2022.
Who can apply for Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 - Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01 - Clinical Trial Optional)?
Closed October 27, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $1.8 million each.
Who has been funded under RFA-DK-22-013?
NIH RePORTER lists 5 projects funded under RFA-DK-22-013 in fiscal 2023 to 2026, at 5 institutions. The most were at Univ of North Carolina Chapel Hill, University of Michigan at Ann Arbor, Indiana University Indianapolis.
Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)